Ulrich T. Hopt

The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs

Ulrich F. Wellner, Jörg Schubert, Ulrike Burk et al. · Nature Cell Biology · 2009 · 1.7K citations

Medicine, Emt-activator Zeb1, Small Rna +5

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Dietrich Alexander Ruess, Guus J.J.E. Heynen, Katrin J. Ciecielski et al. · Nature Medicine · 2018 · 363 citations

Tumor Biology, Mutant Kras-driven Cancers, Cancer Cell Biology +4

The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer

Hartwig Riediger, Tobias Keck, Ulrich F. Wellner et al. · Journal of Gastrointestinal Surgery · 2009 · 343 citations

Surgical Oncology, Pancreatic Cancer, Gastrointestinal Oncology +9

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)

Jens Hoeppner, Florian Lordick, Thomas Brunner et al. · BMC Cancer · 2016 · 343 citations · Full text

<scp>ZEB</scp> 1‐associated drug resistance in cancer cells is reversed by the class I <scp>HDAC</scp> inhibitor mocetinostat

Simone Meidhof, Simone Brabletz, Waltraut Lehmann et al. · EMBO Molecular Medicine · 2015 · 227 citations · Full text